Publication

ACR •
29 October, 2025 •
•

PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome

David B. Beck, Mael Heiblig, Sinisa Savic, Marcela A. Ferrada, Arsene Mekinian, Onima Chowdhury, Danielle Hammond, Lachelle D. Weeks, Carmelo Gurnari, Yohei Kirino , Sophie Georgin-Lavialle, Sarah A. Buckley, Bryan G. Harder, Sandra Goble, Matthew J. Koster

Available materials

Oral Presentation

Publication

ACR •
28 October, 2025 •
•

Characterization of Infusion Reactions Within 1 Hour of Treatment With Nanoencapsulated Sirolimus Plus Pegadricase: Pooled Results From the Phase 3 DISSOLVE I and DISSOLVE II Trials

Herbert Baraf, Andrew Sulich, Guillermo Valenzuela, Rehan Azeem, Ben Peace, Bhavisha Desai, Herbert Baraf

Available materials

Poster

Publication

ACR •
28 October, 2025 •
•

Economic Burden of Macrophage Activation Syndrome (MAS) in Patients with Still’s Disease (Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult-onset Still’s Disease (AOSD): Analysis of a US National Administrative Claims Database

Michael Marrone, Christopher McPherson, Abiola Oladapo

Available materials

Poster

Publication

Reduction in Tophi Observed in Patients With Uncontrolled Gout Treated With NASP: Results From Phase 3 DISSOLVE Studies

PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome

Characterization of Infusion Reactions Within 1 Hour of Treatment With Nanoencapsulated Sirolimus Plus Pegadricase: Pooled Results From the Phase 3 DISSOLVE I and DISSOLVE II Trials

Economic Burden of Macrophage Activation Syndrome (MAS) in Patients with Still’s Disease (Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult-onset Still’s Disease (AOSD): Analysis of a US National Administrative Claims Database

Nanoencapsulated Sirolimus Plus Pegadricase Reduced Disease Burden in Patients With Uncontrolled Gout: Results From the Phase 3 DISSOLVE Trials

PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome

Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS-DAI)

Development of a Consensus Definition of VEXAS Flare for Use in Clinical Research

Putting on your VEXAS goggles: Seeing what’s in plain sight